This federal Project Grant award from the National Institute of Neurological Disorders and Stroke, under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,325,500.00 in funding to The Washington University to develop novel PAC1 receptor antagonists for the treatment of medication overuse headache (MOH).
The grant aims to establish a collaboration between researchers at The Washington University, the University of Southern California, and other partners to identify, characterize, and optimize small molecule antagonists targeting the PAC1 receptor, which has been implicated in MOH pathology. Key activities include virtual screening, computational modeling, medicinal chemistry, pharmacological evaluation, and in vivo testing of promising lead compounds in preclinical models of MOH and migraine. The University of Southern California is serving as a sub-awardee, contributing their expertise in computational chemistry and modeling to support the development of novel PAC1 antagonists.
Generated 2/25/25, 5:01 AM